SCHEMBL662729

SCHEMBL662729

O=C1[N]C(=O)c2[nH]cnc2N1

nearest known ligand 0.40

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GDA Q9Y2T3 2/20 0.40
ATIC P31939 1/20 0.40
ALDH1A1 P00352 2/20 0.32
POLB P06746 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
SRC P12931 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15759316 0.69 GDA (0.39) GDAATICALDH1A1POLBRXFP1
SCHEMBL10104693 0.62 ALDH1A1 (0.38) GDAATICALDH1A1
SCHEMBL28970653 0.61 GDA (0.36) GDAATIC
SCHEMBL22647817 0.60 GDA (0.32) GDAATIC
SCHEMBL1887298 0.58
SCHEMBL13735762 0.58 ALDH1A1 (0.65) GDAATICALDH1A1POLBRXFP1
SCHEMBL5752168 0.57
SCHEMBL13735766 0.56 ALDH1A1 (0.63) GDAATICALDH1A1POLBRXFP1
SCHEMBL12500558 0.56
SCHEMBL2523526 0.56 GDA (0.51) GDAATICALDH1A1POLBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658081-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-05-24 EP claimed
WO-2005021003-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2005-03-10 WO claimed
US-20040077859-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2004-04-22 US claimed
US-20240231224-A9 HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF LAM RESEARCH CORPORATION 2024-07-11 US disclosed
WO-2024137876-A2 SURFACE MODIFICATION OF METAL CATALYSTS WITH HYDROPHOBIC LIGANDS OR IONOMERS TWELVE BENEFIT CORPORATION (US) 2024-06-27 WO disclosed
US-20240200208-A1 CO2 PURIFICATION AND REDUCTION SYSTEMS SUMITOMO MITSUI BANKING CORPORATION 2024-06-20 US disclosed
US-20240192590-A1 APPARATUS AND PROCESS FOR EUV DRY RESIST SENSITIZATION BY GAS PHASE INFUSION OF A SENSITIZER LAM RESEARCH CORPORATION 2024-06-13 US disclosed
WO-2024123514-A1 CO2 PURIFICATION AND REDUCTION SYSTEMS TWELVE BENEFIT CORPORATION (US) 2024-06-13 WO disclosed
WO-2024108304-A1 DITHIOL CHELATORS FOR METAL CONJUGATION TO ANTIBODIES STANDARD BIOTOOLS CANADA INC. (CA) 2024-05-30 WO disclosed
US-20240134274-A1 HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF LAM RES CORP (US) 2024-04-25 US disclosed
WO-2024081174-A1 OXYMETHYLENE COPOLYMERS FOR TRANSIENT SURFACE PROTECTION DURING CHEMICAL VAPOR DEPOSITION LAM RESEARCH CORPORATION (US) 2024-04-18 WO disclosed
WO-2005035121-A2 SCHIFF BASE METAL COMPLEXES FOR USE AS CATALYSTS IN ORGANIC SYNTHESIS UNIVERSITEIT GENT (BE) 2005-04-21 WO disclosed
WO-2005025574-A2 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. 4 AZA BIOSCIENCE NV (BE) 2005-03-24 WO disclosed
WO-2005021003-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2005-03-10 WO disclosed
US-20050043541-A1 Metal complexes useful in metathesis and other reactions RIMTEC CORPORATION (JP) 2005-02-24 US disclosed
WO-2004104005-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2004-12-02 WO disclosed
US-20040077859-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2004-04-22 US disclosed
EP-0733633-B1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-05-28 EP disclosed
US-5753664-A ANTITUMOR AGENTS, PYRIMIDONES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-05-19 US disclosed
EP-0733633-A1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043541-A1 Metal complexes useful in metathesis and other reactions TST, ETFA, TTPA GDA 777/4885ATIC 344/4885ALDH1A1 214/4885
US-20040077859-A1 Immunosuppressive effects of pteridine derivatives TPMT, NFATC1, MALT1 GDA 1888/4885ATIC 1446/4885ALDH1A1 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.